Pharmaguy™’s Twitter Stream – Q1 2012
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Pharmaguy™’s Twitter Stream – Q1 2011
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Pharmaguy™’s Twitter Stream – Q1 2010
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Pharmaguy™’s Twitter Stream – Q1 2009
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Pharmaguy Featured in Videos
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Five Minute or Less Audio Interviews
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Five Minute or Less Audio Interviews
Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
Pharmaguy™ Interviews Dyan Byson: Patient-Centric Marketing: Measure Differently for Healthier Returns
In this 2-minute snippet Dyan Byson, Managing Director, Inspired Health Strategies, LLC, urges pharma marketers to 'measure differently' by going beyond IMS NRx (new prescription) data and following what happens AFTER the prescription is filled to better understand the patient and implement 'patient-centric' marketing.
Bad, Devalued, Distrusted & Defensive Pharma
You know the Tale of Two Cities. This article, however, tells the Tale of Two Books: Bad Pharma, a 430-page book by Ben Goldacre, a British physician, whose previous book, Bad Science, was a best seller in the non-fiction realm and the much smaller 123-page book Devalued and Distrusted by John L. LaMattina, former president of research and develop at Pfizer.
Pharmaguy’s Pharma Predictions
To usher in the New Year, it's traditional for pundits like Pharmaguy (aka John Mack, Publisher of Pharma Marketing News) to go out on a limb and make a few pharma industry predictions for the year. To compile his list, Pharmaguy used data from surveys, interviewed a pharmaceutical executive, and looked at the past year as an indication of what may be important in 2013 and beyond.
